Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUGUSTO E FOCIL

Allopathic & Osteopathic Physicians Family Medicine

NPI
1407906027
CMS profile
336597
Location
OXNARD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,005.14

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $999.88 66
Education $5.26 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUGUSTO E FOCIL

NPI 1407906027 · CMS profile ID 336597

Allopathic & Osteopathic Physicians / Family Medicine

OXNARD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407906027?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407906027?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407906027?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1407906027?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $1,005.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $15.7412/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685641525 CMS
Novo Nordisk Inc $16.4912/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674645271 CMS
Radius Health, Inc. $11.0012/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683970637 CMS
SANOFI-AVENTIS U.S. LLC $21.3612/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694291389 CMS
Novo Nordisk Inc $11.4311/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674645275 CMS
Allergan Inc. $20.4811/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670351625 CMS
Amgen Inc. $29.2211/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662199505 CMS
Janssen Pharmaceuticals, Inc $17.9711/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658586525 CMS
AstraZeneca Pharmaceuticals LP $14.1111/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685681381 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.5710/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681768161 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.7910/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681950157 CMS
Merck Sharp & Dohme Corporation $18.0910/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695820075 CMS
SANOFI-AVENTIS U.S. LLC $24.5210/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694173181 CMS
Janssen Pharmaceuticals, Inc $4.7910/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658586521 CMS
Janssen Pharmaceuticals, Inc $13.2409/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658586517 CMS
AstraZeneca Pharmaceuticals LP $12.5709/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685980017 CMS
SANOFI-AVENTIS U.S. LLC $20.1808/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694136387 CMS
Novartis Pharmaceuticals Corporation $11.7108/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659986207 CMS
AstraZeneca Pharmaceuticals LP $14.0908/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685143021 CMS
Merck Sharp & Dohme Corporation $18.8308/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695708733 CMS
Novo Nordisk Inc $12.3208/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674599969 CMS
Janssen Scientific Affairs, LLC $30.1707/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657592997 CMS
Radius Health, Inc. $29.8907/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683970619 CMS
Amgen Inc. $19.0807/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662199509 CMS
Janssen Pharmaceuticals, Inc $2.5607/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658586513 CMS
AbbVie, Inc. $23.9207/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647724983 CMS
SANOFI-AVENTIS U.S. LLC $21.5606/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694043801 CMS
Janssen Pharmaceuticals, Inc $0.3406/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658586505 CMS
Janssen Pharmaceuticals, Inc $11.4506/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658586509 CMS
Novo Nordisk Inc $12.7006/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674452263 CMS
Janssen Pharmaceuticals, Inc $14.3405/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658586497 CMS
Janssen Pharmaceuticals, Inc $0.7605/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658586501 CMS
Novartis Pharmaceuticals Corporation $17.8605/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659986201 CMS
SANOFI-AVENTIS U.S. LLC $20.7605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694048311 CMS
Novartis Pharmaceuticals Corporation $16.6805/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659986195 CMS
Janssen Pharmaceuticals, Inc $5.2605/10/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658586493 CMS
AstraZeneca Pharmaceuticals LP $16.3605/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685915607 CMS
Abbott Laboratories $15.5804/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664396733 CMS
SANOFI-AVENTIS U.S. LLC $22.7404/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693998909 CMS
Janssen Pharmaceuticals, Inc $11.5404/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658586489 CMS
Janssen Pharmaceuticals, Inc $1.6404/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658586485 CMS
AstraZeneca Pharmaceuticals LP $12.8904/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685767127 CMS
Amarin Pharma Inc. $14.3604/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699120177 CMS
Novo Nordisk Inc $12.3404/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669534867 CMS
Amgen Inc. $16.7303/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662199507 CMS
AstraZeneca Pharmaceuticals LP $15.2503/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685754269 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.8603/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681718477 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.0903/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681997819 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.3803/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682086779 CMS
Novo Nordisk Inc $12.7403/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669486471 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,005.14 67
PY2020 $147.59 10
PY2021 $845.82 44
PY2022 $3,925.76 37
PY2023 $246.04 11
PY2024 $245.24 11
PY2025 $50.47 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,708,235.50 545
PY2024 Principal investigator $1,326,172.95 90
PY2023 Principal investigator $2,591,514.80 142
PY2022 Principal investigator $1,448,426.62 96
PY2021 Recipient $668.48 1
PY2021 Principal investigator $1,836,497.66 79
PY2020 Principal investigator $3,489,260.26 87
PY2019 Principal investigator $210,837.51 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

87 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,000.00 11/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724479067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,200.00 11/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724479069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,800.00 11/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724479071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,800.00 11/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724479073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,000.00 11/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724479075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,000.00 11/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724479077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $116,764.09 11/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724479079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $868,265.91 11/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724479081
Principal investigator 1 Novo Nordisk AS $75.00 11/11/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,600.00 11/09/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724478733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,600.00 11/09/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724478735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,465.37 11/05/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724478643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,800.00 10/29/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724478241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,400.00 10/29/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724478243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,600.00 10/22/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724477773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $76,870.80 10/19/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724477395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200,113.38 10/19/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724477397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,250.00 10/15/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724477153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $953.95 10/15/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724477155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 10/15/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724477157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,800.00 10/15/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724477159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29,800.00 10/12/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,000.00 10/12/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,800.00 10/08/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,800.00 10/08/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,200.00 10/08/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,600.00 10/08/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,400.00 10/08/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,400.00 10/08/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INCORPORATED
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,600.00 09/29/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724476189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,200.00 09/29/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 09/29/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,300.00 09/29/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724476195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,100.00 09/29/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $438,606.38 09/28/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724476121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,800.00 09/28/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724476123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,200.00 09/24/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724475869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,600.00 09/24/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724475871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,400.00 09/24/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724475873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39,493.03 09/17/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724475087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,600.00 09/10/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,400.00 09/10/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,046.05 09/10/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,534.63 09/10/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724474857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 09/08/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 09/08/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,250.00 09/08/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724474763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 08/31/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724474355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 08/31/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724474357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 08/31/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724474359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,000.00 08/31/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724474363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 08/31/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,000.00 08/31/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 08/31/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 08/31/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57,532.68 08/27/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724474307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,200.00 08/27/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,600.00 08/27/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724474311
Principal investigator 1 Novo Nordisk AS $1,250.00 08/25/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 742444953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 08/25/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $123,857.09 08/25/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724474083
Principal investigator 1 Novo Nordisk AS $625.00 06/23/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 742444949
Principal investigator 1 Novo Nordisk AS $625.00 05/28/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 742444909
Principal investigator 1 Novo Nordisk AS $1,250.00 04/28/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 742444907
Principal investigator 1 Novo Nordisk AS $1,000.00 04/23/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444911
Principal investigator 1 Novo Nordisk AS $7,500.00 04/23/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444913
Principal investigator 1 Novo Nordisk AS $2,500.00 04/23/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444915
Principal investigator 1 Novo Nordisk AS $1,250.00 03/24/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 742444905
Principal investigator 1 Novo Nordisk AS $117.78 02/27/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444919
Principal investigator 1 Novo Nordisk AS $75.00 02/27/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444921
Principal investigator 1 Novo Nordisk AS $625.00 01/28/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 742444903
Principal investigator 1 Novo Nordisk AS $25.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444923
Principal investigator 1 Novo Nordisk AS $56.90 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444925
Principal investigator 1 Novo Nordisk AS $32.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444927
Principal investigator 1 Novo Nordisk AS $32.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444929
Principal investigator 1 Novo Nordisk AS $32.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444931
Principal investigator 1 Novo Nordisk AS $32.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444933
Principal investigator 1 Novo Nordisk AS $32.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444935
Principal investigator 1 Novo Nordisk AS $32.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444937
Principal investigator 1 Novo Nordisk AS $32.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444939
Principal investigator 1 Novo Nordisk AS $32.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444941
Principal investigator 1 Novo Nordisk AS $32.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444943
Principal investigator 1 Novo Nordisk AS $32.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444945
Principal investigator 1 Novo Nordisk AS $32.50 01/16/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 742444947
Principal investigator 1 Novo Nordisk AS $5,029.80 01/14/2020 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN2211-4232 No dispute reported 06/30/2026 742444917
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $133,982.24 01/03/2020 Non-covered Recipient Entity
Fomat Medical Research Incorporated
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF21) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 LIVER FIBROSIS No dispute reported 06/30/2026 736759825
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,662.18 01/03/2020 Non-covered Recipient Entity
Fomat Medical Research Incorporated
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF21) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND COMPENSATED LIVER CIRRHOSIS No dispute reported 06/30/2026 736759827